Valbiotis Sas Stock Fundamentals

ALVAL Stock  EUR 1.39  0.02  1.46%   
Valbiotis SAS fundamentals help investors to digest information that contributes to Valbiotis SAS's financial success or failures. It also enables traders to predict the movement of Valbiotis Stock. The fundamental analysis module provides a way to measure Valbiotis SAS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Valbiotis SAS stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Valbiotis SAS Company Shares Outstanding Analysis

Valbiotis SAS's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Valbiotis SAS Shares Outstanding

    
  12.41 M  
Most of Valbiotis SAS's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Valbiotis SAS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Based on the latest financial disclosure, Valbiotis SAS has 12.41 M of shares currently outstending. This is 93.13% lower than that of the Biotechnology sector and 88.39% lower than that of the Health Care industry. The shares outstanding for all France stocks is 97.83% higher than that of the company.

Valbiotis SAS Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Valbiotis SAS's current stock value. Our valuation model uses many indicators to compare Valbiotis SAS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Valbiotis SAS competition to find correlations between indicators driving Valbiotis SAS's intrinsic value. More Info.
Valbiotis SAS is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Valbiotis SAS's earnings, one of the primary drivers of an investment's value.

Valbiotis Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Valbiotis SAS's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Valbiotis SAS could also be used in its relative valuation, which is a method of valuing Valbiotis SAS by comparing valuation metrics of similar companies.
Valbiotis SAS is currently under evaluation in shares outstanding category among its peers.

Valbiotis Fundamentals

About Valbiotis SAS Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Valbiotis SAS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Valbiotis SAS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Valbiotis SAS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. Valbiotis SA was founded in 2014 and is based in Prigny, France. VALBIOTIS is traded on Paris Stock Exchange in France.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Valbiotis Stock Analysis

When running Valbiotis SAS's price analysis, check to measure Valbiotis SAS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Valbiotis SAS is operating at the current time. Most of Valbiotis SAS's value examination focuses on studying past and present price action to predict the probability of Valbiotis SAS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Valbiotis SAS's price. Additionally, you may evaluate how the addition of Valbiotis SAS to your portfolios can decrease your overall portfolio volatility.